Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Schering-Plough
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Scheduled for PCI, including PCI for non-ST elevation acute coronary syndromes (ACS), primary PCI for ST elevation myocardial infarction (MI) or elective PCI (with planned overnight stay in hospital). (Patients undergoing diagnostic heart catherization who are suitable candidates for "ad hoc" PCI are also eligible).
You may not be if
Age \< 21 years
Activated Clotting Time (ACT) \> 200 seconds immediately prior to PCI
Use of low molecular weight heparin (LMWH) in the previous 6 hours before PCI
Currently receiving an oral anticoagulant (OAC) agent with an INR \> 1.8
Thrombolytic therapy for ST elevation MI in the previous 24 hours before PCI
Active internal bleeding or history of hemorrhagic diathesis
Thrombocytopenia (platelet count \< 100 x 10-9/L)
Pregnant women or women of childbearing potential who are not using an effective method of contraception
Known allergy to unfractionated heparin, fondaparinux, aspirin or clopidogrel
Absolute contra-indication to anticoagulation
Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment or prior participation in this study.
Clareo Health | A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
